A mutant fibrinogen that is unable to form fibrin can improve renal phenotype in mice with sickle cell anemia.

Autor: Narciso MG; Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA., Hoeting B; Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA., James JM; Division Pediatric Cardiology Medical College of Wisconsin Milwaukee Wisconsin USA., VandenHeuvel K; Pathology Core Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.; University of Cincinnati College of Medicine Cincinnati Ohio USA., Nasimuzzaman M; Division of Experimental Hematology and Cancer Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.; University of Cincinnati College of Medicine Cincinnati Ohio USA.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2021 Jun 15; Vol. 2 (3), pp. 462-465. Date of Electronic Publication: 2021 Jun 15 (Print Publication: 2021).
DOI: 10.1002/jha2.204
Abstrakt: Sickle cell anemia (SCA) causes nephropathy which may progress to kidney failure. To determine if soluble fibrinogen (Fib AEK ) can prevent kidney damage in mice with SCA, we performed bone marrow transplantation (BMT) of Berkeley sickle mice into wild-type fibrinogen (Fib WT ), and Fib AEK mice that bear a germ-line mutation in fibrinogen Aα chain at thrombin cleavage site which prevents fibrin formation. We found improved albuminuria in SS Fib AEK mice compared with SS Fib WT mice at 12 months post-BMT due to the reduced kidney fibrosis, ischemic lesions, and increased survival of podocytes in the glomeruli, but did not improve urine concentrating defect. Therefore, our study clarifies the distinct role of fibrinogen and fibrin in the renal pathology of SCA.
Competing Interests: The authors do not have any conflict of interest to declare.
(© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: